Recent investigations have focused on the convergence of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and DA communication. While GCGR stimulators are increasingly employed for addressing type 2 diabetes, their unexpected effects on motivation circuits, specifically governed by dopaminergic pathways, are gaining substantial … Read More